Wortmannin

For research use only.

Catalog No.S2758 Synonyms: KY 12420

150 publications

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 176 In stock
USD 110 In stock
USD 170 In stock
USD 270 In stock
USD 747 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Wortmannin has been cited by 150 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 NUDUfJM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfqNk42KM7:TR?= MUmxMVQh\A>? MnfySG1UVw>? NITqTGZmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIITy[YF1dWWwdDD3bZRpKHSjbX;4bYZmdg>? Mnn0NlU1QTB|OEO=
H1703 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37S[|IvPSEQvF2= M4f3eVEuPCCm MVjEUXNQ NH;J[4xmdmijbnPld{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIITy[YF1dWWwdDD3bZRpKHSjbX;4bYZmdg>? NXfLZ2lrOjV2OUCzPFM>
HUVECs Mlm1R5l1d3SxeHnjbZR6KEG|c3H5 M2HkNlExOCCwTR?= MUKyOEBp M3;NN4F1fGWwdXH0[ZMhfGinIHHido9o[XSrdnWg[YZn\WO2czDv[kBk[Wy7Y3;zbY4hd25iVmLJMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M3PhN|I2PDVyMUi2
APRE-19 NXi5bG1LSXCxcITvd4l{KEG|c3H5 Mn3iOUDPxE1? NWfkeIhwOjRiaB?= NV;KPGFY[WKxbHnzbIV{KE[OWj3t[YRq[XSnZDDwdo8ue3W{dnn2ZYww[W62aT3hdI9xfG:|aYOgZYN1cX[rdIm= M{\h[FI2OzJ7NkG3
MDA-MB-231 MYLBdI9xfG:|aYOgRZN{[Xl? MYmxxsDPxE4EoB?= MnTWOFghcA>? NE\B[phFVVOR M33X[IRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEB1emWjdHXkJJdqfGhiMkWg{txOKG:oIF[xJI9zKEZ{INMg MViyOVMxODl|Mh?=
MCF7 MWTGeY5kfGmxbjDBd5NigQ>? NXy5ZllSOTByIH7N MV2yOEBp MXPlcIlucW6jdHXzJGUzNWmwZIXj[YQhSVKHLVz1Z{Bi[3Srdnn0fS=> MorwNlUyPzJ3NUe=
HT-29  Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLTNU42yqEEtV2= NI\Pblg6PiCq MkjX[IVkemWjc3XzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDpcohq[mm2ZXSgZpkhU1mQQR?= MY[yOVAyOjF{Mx?=
MO59K  NWLmTmRUS3m2b4TvfIlkcXS7IFHzd4F6 M2TXbVXDqM7:TR?= NWjiZYtCPyCm MXLEUXNQ M{L0VYVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= M4rxTVI1QTV|NU[x
MO59J NEjv[VBEgXSxdH;4bYNqfHliQYPzZZk> NXzTXI9TPcLizszN NHnPcIs4KGR? M1PxXWROW09? NUjVTot3\W6qYX7j[ZMhfGinIHP5eI91d3irY3n0fUBw\iCndH;wc5Nq\GVib4KgZ4l{eGyjdHnu M4i3b|I1QTV|NU[x
MO59K  MYTBdI9xfG:|aYOgRZN{[Xl? NWD6ZppmOTBizszN MYmyOEBp MVLEUXNQ NWqyeYJ{cW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NFixflYzPDl3M{W2NS=>
MO59J M1TIUGFxd3C2b4Ppd{BCe3OjeR?= MlPXNVAh|ryP MoD3NlQhcA>? MYrEUXNQ NHGx[mVqdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? MXKyOFk2OzV4MR?=
HepG2 MlnrSpVv[3Srb36gRZN{[Xl? MX6xNFAhdk1? MmjkNE42KGh? Mk\CSG1UVw>? NUm2PIhm[myxY3vzJG1CNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M1LpW|I1QDZ|M{Ww
A549  M2HrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jFNFMhyrWPwrC= NIrrbowzKGh? NFnuW|Z{fXCycnXzd4V{KHCnbXX0doV5\WRvaX7keYNm\CCDa4SgZY5lKEeVS{ROtkBi[3SrdnH0bY9vNCCVLYDoZZNmKGG{cnXzeEwh[2WubDDhdI9xfG:|aYOgZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:w M1ntRlI1QDR5OE[z
A549  NVq3PHFITnWwY4Tpc44hSXO|YYm= MmfkNVDDqM7:bdMg MWCxOkBp MonPSG1UVw>? MkGycY9lfWyjdHXzJJRp\SCLQW[gdoVxdGmlYYTpc44h[W6mIHPheZNmeyC{ZYTlcpRqd25ib3[gUnAhcW5idHjlJI52[2yndYOu Mnn4NlQ5ODJzMUG=
SK-N-LO M3zuV2Z2dmO2aX;uJGF{e2G7 MXKxNFAhdk1? NHfafoMxNjViaB?= M1HJdoRm[3KnYYPld{B1cGVic4TpcZVt[W62IHXm[oVkfHNib3[gcY9zeGirbnWgc44hSWu2IIDoc5NxcG:{eXzheIlwdg>? MoPtNlQ3PTR4ME[=
HL-60 M2XrV2Z2dmO2aX;uJGF{e2G7 NEfmVo8xNjIEoN88US=> NEnBRlY4OiCq NWLNWWpI[myxY3vzJIRie2G2aX7pZk1qdmS3Y3XkJINmdGxiZHnm[oVz\W62aXH0bY9v MoHVNlQ3ODd{N{O=
HepG2  M3rW[mZ2dmO2aX;uJGF{e2G7 M125WlIxOCCwTR?= M3TEdlAvPSCq MojYZZR1\W63YYTld{BHd3iRIIDoc5NxcG:{eXzheIlwdg>? MlLqNlQ2OzVzOUK=
H520 M3zBOWZ2dmO2aX;uJGF{e2G7 MYCxNOKh|ryP NEW2bmcyKGh? NYf5b3RITE2VTx?= M{fVcoRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> MXSyOFQ1Pzl|NR?=
H1975 MniySpVv[3Srb36gRZN{[Xl? MUexNOKh|ryP NUj6bmp1OSCq NUW0S5hkTE2VTx?= MlzX[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz M{Lpd|I1PDR5OUO1
MG-63 MUfBdI9xfG:|aYOgRZN{[Xl? NVLhPHlWOTBiwsXN MlziNVIhcA>? M3;yToVvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ MXmyOFM2QDNyMR?=
5637 MVHBdI9xfG:|aYOgRZN{[Xl? NWfRSHp4OTEEoN88US=> Mnn0OFAhdWmw M{fYZZJmfmW{c3XzJJAzOVeDRkGg[ZhxemW|c3nvckwhS0SNIHX4dJJme3Orb36sJIFv\CClZXzsJIlvcGmkaYTpc44hcW6mdXPl[EBjgSCodXPvbYRidg>? NYrTW3l[OjR|M{O4Olg>
HEK-293 M3juNGZ2dmO2aX;uJGF{e2G7 MYGxOVBvVQ>? MUCxOkBp MmCzSG1UVw>? MmrM[IVkemWjc3XzJGNTXCCjY4Tpeol1gQ>? MlO4NlQ{OjR|Nk[=
SW480  NGTG[HpHfW6ldHnvckBCe3OjeR?= MV2xOVBvVQ>? MkjUNlAhcA>? MXXEUXNQ M2rQO5Jm\HWlZYOgZ4VtdHWuYYKgZYNkfW23bHH0bY9vKG:oIN8yMYNifGWwaX6= NYf2S4Q6OjR|MkSzOlY>
HepG2 MYTGeY5kfGmxbjDBd5NigQ>? NUTN[2xxOTByIH7N NFH6WZYzPCCq MXnheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? NXzuOpY3OjR{OUe1NVA>
HCT 116  NHrYXIJHfW6ldHnvckBCe3OjeR?= MXGxNFAhdk1? MX:yOEBp NXG1N5dS[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NWDiUVVNOjR{OUe1NVA>
BEL/FU M{CyZmZ2dmO2aX;uJGF{e2G7 NUG5VYttOSCvTR?= MVmyOEBp Mknl[IVkemWjc3XzJJBzd3SnaX6gcIV3\Wy|IH;mJJRp\SCSSUPLM2FsfCCyYYToe4F6 MWSyOFI{OjB7OR?=
Huh7  MX7GeY5kfGmxbjDBd5NigQ>? M2DQNVPDqM7:TR?= MYCxJIg> MlridoVlfWOnczD0bIUhfmm{dYOg[Y51enliaX70c{B1cGViY3XscJM> NWTV[VZZOjRzOESxPVY>
A-375 NG\VfHpCeG:ydH;zbZMhSXO|YYm= NUew[5pMPC96IN88US=> NVW4VoZiOjRiaB?= NFOydmFmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MXWyOFEyOzF5Mx?=
A-375-TS  M4fuZmFxd3C2b4Ppd{BCe3OjeR?= MoriOE85KM7:TR?= NYHTepFiOjRiaB?= MULlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MY[yOFEyOzF5Mx?=
Mel-HO M2PC[GFxd3C2b4Ppd{BCe3OjeR?= NVnrPVFjPC96IN88US=> NH\RZWUzPCCq NXLHPYJb\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MojRNlQyOTNzN{O=
Mel-HO-TS MVjBdI9xfG:|aYOgRZN{[Xl? M1;STFQwQCEQvF2= M323XlI1KGh? M4HyfIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NVX5NnJDOjRzMUOxO|M>
MeWo M{fRZ2Fxd3C2b4Ppd{BCe3OjeR?= MoHiOE85KM7:TR?= NIrQSHMzPCCq MnLM[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MXqyOFEyOzF5Mx?=
Mel-2a MUPBdI9xfG:|aYOgRZN{[Xl? MXK0M|gh|ryP M2fmUlI1KGh? NGD0bWxmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg M1LrU|I1OTF|MUez
MDA-MB-231 NW[4OZEyTnWwY4Tpc44hSXO|YYm= MoT3NQKBmzRyMDDuUS=> MX60JIg> MYDzeZBxemW|c3XzJGFsfCCyaH;zdIhwenmuYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M13oVVIzQTB4MkW5
MDA-MB-231 MWTGeY5kfGmxbjDBd5NigQ>? M17aXFQxOCCwTR?= MmmxOEBp MkLy[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUjpbWlWOjJ7ME[yOVk>
Jurkat M1f0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUewMlI2NTFwMkWg{txO NVjReJBNOjRxNEigbC=> MXLEUXNQ NWrvTWNscW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= M{PFcVE6PzV5MUi1
Namalwa M4DzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXJNE4zPS1zLkK1JO69VQ>? NHrhb4YzPC92ODDo NF\ObJdFVVOR NGPrb|ZqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= NXTMOm1mOTl5NUexPFU>
Jurkat NXLrOWY2SXCxcITvd4l{KEG|c3H5 NUXDcWRyOC5{NT2xMlI2KM7:TR?= M33OOFI1NzR6IHi= M2XqUWROW09? NUfmTos2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz NWPCWGZzOTl5NUexPFU>
Namalwa NUHndnBnSXCxcITvd4l{KEG|c3H5 NGLXVZExNjJ3LUGuNlUh|ryP NXe5VlFlOjRxNEigbC=> MUjEUXNQ NFq5XHFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NF;LW3cyQTd3N{G4OS=>
K562 NVTRPW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWyOEBp NEj0S5ZKSzVyPUK1xtExNjF2IH7N NHuzdlUyQTZ4MkO2NS=>
SW1990 NXX4dGxUTnWwY4Tpc44hSXO|YYm= NGH6XnIxNjBzLUGg{txO NULxUG5yOSCq M3;mSIlvcGmkaYTzJGhCNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M3LuTFE6PDZ7MEKw
RT112  NH;SSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV30enVxOTEEoN88US=> MnLnNlQhcA>? MnnySG1UVw>? MnL6[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> M4ftN|E5Pzh5OEOy
MHG-U1 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorLNVDDqM7:TR?= MoDSNlQhcA>? NV7veoJnTE2VTx?= MXHk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gS|IwVSClZXzsdy=> NWjGcGJqOTh5OEe4N|I>
SMMC-7721 MVvBdI9xfG:|aYOgRZN{[Xl? NHi0V2gzODEEoH7N M{DDVFI1KGh? MnHUbY5kemWjc3XzJGNJYC2rbnT1Z4VlKGGyb4D0c5Nqew>? M4LXd|E4PTV5MUmx
SMMC-7721 M4G5dmZ2dmO2aX;uJGF{e2G7 NFP2XYYzODEEoH7N Mn;iNlQhcA>? Ml;UeZAuemWpdXzheIV{KM7{MTy0S3QyKGW6cILld5Nqd25? MWKxO|U2PzF7MR?=
HeLa M1TRRWZ2dmO2aX;uJGF{e2G7 NGDWTXMyODEEoH7NxsA> MYWxJIg> MWXhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJRz[W6|ZnXydolvKHKnY4njcIlv\yClb33wZZJ1dWWwdB?= M2f3eVE3QDlyOUG1
MRC5VI NUfhdolPTnWwY4Tpc44hSXO|YYm= M4DZPVEzNjVibV2= MkLHNE42KGh? M4Hie2ROW09? MYThZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> MoXFNVYzOjd|OUS=
AT5BIVA M4rES2Z2dmO2aX;uJGF{e2G7 MWWxNk42KG2P NVXwXJdxOC53IHi= NGT6e4ZFVVOR M3rCeIFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NHzzcY0yPjJ{N{O5OC=>
M059J MV;GeY5kfGmxbjDBd5NigQ>? NFLDd4oyOi53IH3N NWjkV4FWOC53IHi= M1;mSmROW09? MmLnZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> M1vxfFE3OjJ5M{m0
HeLa MVLGeY5kfGmxbjDBd5NigQ>? MlzFNVIvPSCvTR?= NFL2e48xNjViaB?= M{LJ[GROW09? NEjpUJJi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? Mn[4NVYzOjd|OUS=
N2a M1rnTmFxd3C2b4Ppd{BCe3OjeR?= NXPHPG9lOC5zLUGwJO69VQ>? NGq4UW8zKGh? MVHpcoR2[2W|IHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NYfCUYV3OTV6NEK3Olc>
Jurkat  MUTLbY5ie2ViQYPzZZk> M2S2NGlEPTBib3[gNlQhdk1? NHHIWoQyPTZ4NEWxPS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
- Collapse
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID